Skip to main content

Table 3 Comparison between dopaminergic drug responsive fatigue (DDRF) and dopaminergic drug non-responsive fatigue (DDNRF)

From: Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Variable DDRF DDNRF p
Male (n= 79) 13 (38.24 %) 24 (53.33 %) 0.354
Age, y (n= 79) 59.59 ± 8.89 63.64 ± 11.80 0.074
Onset age, y (n= 79) 54.24 ± 8.95 58.82 ± 11.93 0.040*
Duration of disease (n= 79) 5.35 ± 3.02 4.82 ± 3.24 0.276
Education, y (n= 79) 10.03 ± 2.93 9.36 ± 4.23 0.681
LEDD (mg/day) (n= 79) 473.38 ± 281.42 438.26 ± 271.25 0.804
H-Ystage (n= 79) 2.15 ± 0.82 2.04 ± 0.74 0.526
UPDRS total (n= 79) 55.94 ± 21.46 52.91 ± 20.22 0.674
UPDRS I (n= 79) 4.06 ± 2.15 3.87 ± 2.61 0.506
UPDRS II (n= 79) 13.00 ± 5.65 13.59 ± 6.36 0.67
UPDRS III (n= 79) 36.76 ± 15.50 33.63 ± 14.67 0.362
Gait (n= 79) 5.12 ± 3.15 5.26 ± 3.41 0.843
Tremor (n= 79) 4.32 ± 4.20 320 ± 3.89 0.19
Rigidity (n= 79) 7.56 ± 4.59 6.20 ± 4.19 0.198
Bradykinesia (n= 79) 16.94 ± 7.50 16.38 ± 7.47 0.741
UPDRS IV (n= 79) 2.11 ± 2.77 1.82 ± 2.70 0.541
HAMD (n= 70) 7.66 ± 4.51 (N= 32) 10.66 ± 4.70 (N= 38) 0.006*
PDSS (n= 70) 107.81 ± 25.33 (N= 32) 97.26 ± 25.98 (N= 38) 0.073
MoCA (n= 79) 22.47 ± 4.14 21.42 ± 4.59 0.353
  1. Data are expressed as numbers, with percentages in parentheses, or as mean ± SD. *Significant difference. DDRF dopaminergic drug responsive fatigue, DDNRF dopaminergic drug non-responsive fatigueH-Y stage: Hoehn & Yahr staging, LEDD levodopa equivalent daily dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA Montreal Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS Parkinson’s Disease Sleep Scale